| Dr Robert K Saito, MD | |
|
77-311 Sunset Dr, Kailua-kona, HI 96745 | |
| (808) 329-7314 | |
| (808) 329-5510 |
| Full Name | Dr Robert K Saito |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 33 Years |
| Location | 77-311 Sunset Dr, Kailua-kona, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770540312 | NPI | - | NPPES |
| 08098101 | Medicaid | HI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hilo Medical Center | Hilo, HI | Hospital |
| Kona Community Hospital | Kealakekua, HI | Hospital |
| Wahiawa General Hospital | Wahiawa, HI | Hospital |
| Kau Hospital | Pahala, HI | Hospital |
| Sky Ridge Medical Center | Lone tree, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hawaii Radiologic Associates Ltd | 0941190953 | 76 |
| Kahuku Medical Center | 1557446697 | 11 |
| Radiology Imaging Associates Pc | 2860391257 | 138 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago
| Entity Name | Hawaii Radiologic Associates Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174679443 PECOS PAC ID: 0941190953 Enrollment ID: O20040316000098 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago
| Entity Name | Kahuku Medical Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1245430065 PECOS PAC ID: 1557446697 Enrollment ID: O20080312000783 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago
| Entity Name | Kahuku Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902087109 PECOS PAC ID: 1557446697 Enrollment ID: O20100918000238 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago
| Entity Name | Radiology Imaging Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679513196 PECOS PAC ID: 2860391257 Enrollment ID: O20140528001077 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago
| Entity Name | Medical Imaging Of Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336188234 PECOS PAC ID: 5395644702 Enrollment ID: O20221212000497 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert K Saito, MD 10800 E Geddes Ave Ste 300, Englewood, CO 80112-3895 Ph: (720) 295-9593 | Dr Robert K Saito, MD 77-311 Sunset Dr, Kailua-kona, HI 96745 Ph: (808) 329-7314 |
News Archive
A discovery made 25 years ago about how the brain controls blood pressure regulation is only now being explored with the help of scientists from the Howard Florey Institute.
A declaration affirming that non-discrimination is fundamental to an evidence-based response to HIV and effective public health programmes was announced today by the organizers of the 20th International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia, from 20-25 July 2014.
Savient Pharmaceuticals, Inc. announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented at the American College of Rheumatology (ACR) Annual Scientific Meeting in Chicago.
Results of the randomized, phase III, EORTC/GIMEMA 06012 intergroup trial (AML-17) reported in the Journal of Clinical Oncology show that sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit for older patients with acute myeloid leukemia (AML) and is too toxic for patients 70 years of age or more. GO is an antibody-drug conjugate comprised of an anti-CD33 monoclonal antibody linked to a cytotoxic agent.
St. Jude investigators have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
› Verified 1 days ago